[144] OMEROS CORP SEC Filing
This article reports on a Form 144 SEC filing by OMEROS CORP (OMER) dated May 22, 2026. The filing indicates a proposed sale of 7,500 shares of common stock with an aggregate market value of $89,700, acquired through the exercise of stock options, to be sold on NASDAQ via Morgan Stanley Smith Barney LLC. The document details the filer and issuer information, securities to be sold, and confirms no material adverse information is known by the seller that has not been publicly disclosed.
Omeros gets FDA approval for YARTEMLEA as first therapy for TA-TMA
Omeros has received FDA approval for YARTEMLEA (narsoplimab) as the first and only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adult and pediatric patients. This significant milestone addresses a critical unmet medical need for a rare and life-threatening complication of stem cell transplantation, which previously had no FDA-approved therapies. The approval comes after a thorough review of clinical data demonstrating improved outcomes with the drug.
Earnings call transcript: Omeros Q1 2026: Stock dips after earnings miss
Omeros Corporation reported a significant earnings and revenue miss for Q1 2026, with an EPS of -$0.24 against a forecast of -$0.12, and revenue of $9.89 million against an expected $40.15 million. This led to a 10.03% drop in stock price in after-hours trading, despite successful commercialization efforts for its lead product, YARTEMLEA, and a strong cash position. The company is focusing on driving positive cash flow through YARTEMLEA, expanding its indications, and advancing other pipeline programs.
OMER Stock Gains Ground As Commercial Rollout Of Yartemlea Exceeds Expectations
Omeros Corporation (OMER) shares rose over 4% after the company reported strong first-quarter commercial revenue for YARTEMLEA, exceeding Wall Street expectations with $9.9 million in net sales. The adjusted net loss also narrowed, and operating expenses decreased significantly due to the sale of an experimental drug asset. The company is anticipating a European marketing authorization decision for YARTEMLEA and continues to advance its pipeline, leading to bullish sentiment among retail traders.
Omeros Corporation (NASDAQ:OMER) Q1 2026 Earnings Call Transcript
Omeros Corporation reported strong Q1 2026 results, driven by the successful launch of YARTEMLEA, its new drug for TA-TMA. The company exceeded earnings expectations, achieved $9.9 million in net revenues for YARTEMLEA, and ended the quarter with $135.3 million in cash. Omeros anticipates YARTEMLEA will become the standard of care for TA-TMA and is pursuing pipeline expansion and global partnerships.
How Omeros’ (OMER) Noncash-Boosted Q1 Profit Swing Will Impact Investors
Omeros Corporation reported a significant Q1 2026 profit swing driven by noncash items, with sales of US$9.89 million and a net income of US$56.06 million. While this performance does not alter the core investment thesis around YARTEMLEA's launch, it highlights the impact of accounting adjustments on reported earnings. Investors are advised to differentiate between accounting volatility and actual product revenue growth, with current forecasts projecting substantial revenue and earnings increases by 2029.
How Omeros’ (OMER) Noncash-Boosted Q1 Profit Swing Will Impact Investors
Omeros Corporation reported a significant Q1 2026 profit swing, moving from a net loss to a net income of US$56.06 million, primarily driven by noncash items, with sales reaching US$9.89 million. While the profit rise is notable, the core investment narrative remains tied to the commercial success and regulatory execution of its lead drug, YARTEMLEA. Investors are advised to differentiate between accounting volatility from noncash adjustments and the actual revenue trajectory from the new therapy.
Earnings call transcript: Omeros misses Q1 2026 expectations, stock dips
Omeros Corporation reported a significant miss on both EPS and revenue for Q1 2026, with an EPS of -$0.24 against a forecast of -$0.12, and revenue of $9.89 million against an anticipated $40.15 million. Despite the financial setbacks, the company's lead product, YARTEMLEA, achieved FDA approval and strong early market adoption, contributing $9.9 million in net revenues and becoming cash flow positive in its first quarter. Omeros remains optimistic about YARTEMLEA's growth, expecting company-wide positive cash flow within 18 months, supported by strategic partnerships and ongoing efforts to expand market access and adoption, including upcoming J-code and NTAP benefits.
BRIEF-Omeros Corporation Q1 EPS USD 0.78
Omeros Corporation (OMER) reported its Q1 Earnings Per Share (EPS) at USD 0.78. This brief announcement was made by Refinitiv and disseminated via TradingView News.
OMER stock gains ground as commercial rollout of Yartemlea exceeds expectations
Omeros Corporation (OMER) stock is experiencing gains due to the stronger-than-anticipated commercial rollout of its drug, Yartemlea. This success suggests a positive outlook for the company's financial performance following recent FDA approval.
OMER stock gains ground as commercial rollout of Yartemlea exceeds expectations
The article reports that Omeros Corporation's stock (OMER) is increasing in value following the commercial launch of its drug, Yartemlea. The rollout is performing better than initial expectations, indicating positive market reception for the new product.
Omeros: Q1 Earnings Snapshot
Omeros Corporation (OMER) reported a Q1 profit of $56.1 million, or 62 cents per share. After adjustments for non-recurring gains and discontinued operations, the company experienced a loss of 24 cents per share. The drug developer generated $9.9 million in revenue during the first quarter.
New transplant drug gains Medicare billing code, logs $11M sales
Omeros Corporation reported strong first-quarter 2026 financial results, driven by the successful launch of YARTEMLEA®, an FDA-approved drug for TA-TMA. The company posted a net income of $56.1 million and $9.9 million in net sales for YARTEMLEA. Additionally, YARTEMLEA secured a permanent Medicare J-code and is recommended for New Technology Add-On Payment (NTAP), which significantly improves its billing and reimbursement landscape.
Omeros: Q1 Earnings Snapshot
Omeros Corporation (OMER) reported a first-quarter profit of $56.1 million, or 62 cents per share. After adjustments for non-recurring gains and discontinued operations, the company experienced a loss of 24 cents per share. The Seattle-based drug developer also recorded revenues of $9.9 million for the period.
Omeros Corporation Reports First Quarter 2026 Financial Results
Omeros Corporation announced its first-quarter 2026 financial results, highlighted by the launch of YARTEMLEA® in the U.S. and a significant increase in net income to $56.1 million, or $0.78 per share, compared to a net loss in the prior year. The company reported $9.9 million in net product sales for YARTEMLEA and detailed progress across its pipeline, including a permanent J-code assignment for YARTEMLEA and advancements in its MASP-2 inhibitor, oncology, and addiction treatment programs.
Omeros: Q1 Earnings Snapshot
Omeros Corporation reported a profit of $56.1 million in its first quarter, translating to 62 cents per share. The Seattle-based drug developer also noted adjusted losses of 24 cents per share and total revenue of $9.9 million for the period.
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026
Omeros Corporation announced that it would release its first-quarter financial results on May 13, 2026. The announcement was made via a press release highlighted by Quantisnow, a platform that provides real-time market data and news for investors. Quantisnow Plus members received an alert regarding this announcement seconds after its publication.
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026
Omeros Corporation is scheduled to release its first-quarter financial results on May 13, 2026, after the market closes. The company will then host a conference call to discuss these results and provide further financial insights. Interested parties will be able to access this call for additional information.
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026
Omeros Corporation (NASDAQ: OMER) announced it will release its first-quarter 2026 financial results on Wednesday, May 13, 2026, after market close. The company will host a conference call and webcast on the same day to discuss developments and financial results. Omeros also provided details on its pipeline, including its FDA-approved drug YARTEMLEA® and other clinical-stage programs.
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026
Omeros Corporation announced that it will release its first-quarter 2026 financial results on Wednesday, May 13, 2026, after market close. Following the release, Omeros management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and recent developments. The company is transitioning to a new earnings call platform and advises participants to allow extra time for log-in.
Omeros earnings up next as investors eye YARTEMLEA launch By Investing.com
Omeros Corporation is set to report its first-quarter earnings, with investors keenly focused on the commercial debut of its new drug, YARTEMLEA, for a rare transplant complication. Analysts expect a loss of 12 cents per share, a significant shift from the previous quarter's profit which included a large one-time gain from an asset sale. The market will be watching for YARTEMLEA's traction, capital allocation strategies, and updated guidance on the company's path to financial self-sustainability.
100% Of This Omeros Insider's Holdings Were Sold
This article reports that an insider at Omeros sold 100% of their holdings in the company. No further details are provided regarding the insider's identity, the reason for the sale, or the financial implications. The content suggests the article is incomplete.
UBS Group AG Grows Position in Omeros Corporation $OMER
UBS Group AG significantly increased its stake in Omeros Corporation (NASDAQ:OMER) by 213.5% in the fourth quarter, now owning 3.14% of the company valued at $38.18 million. Despite Omeros reporting a surprise quarterly EPS of $3.14, analysts maintain a "Moderate Buy" consensus with an average price target of $40.33, while the stock currently trades around $14.64. The biopharmaceutical company has a market cap of $1.06 billion and has experienced substantial volatility over the past year.
Assessing Omeros (OMER) Valuation After Recent Share Price Rebound And Novo Nordisk Deal Prospects
Omeros (OMER) has shown significant share price rebound over the last three months, despite a year-to-date decline and no current product revenue. The company's valuation narrative suggests it is 61% undervalued with a fair value of $38, largely based on the expected closing of a US$2.1 billion deal with Novo Nordisk, which would alleviate debt and extend its cash runway. However, this optimistic outlook depends on timely cash flows from Novo Nordisk and regulatory approval for its drug YARTEMLEA, alongside inherent risks in its clinical-stage pipeline.
Omeros Corporation (NASDAQ:OMER) Given Average Rating of "Moderate Buy" by Analysts
Omeros Corporation (NASDAQ:OMER) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month target price of $40.33. This comes despite mixed financial results, including a significantly higher-than-expected EPS for the last quarter but a projected negative EPS for the current fiscal year. Key institutional investors, such as JPMorgan Chase & Co., have substantially increased their holdings in the company.
OMEROS CORP ($OMER) CEO 2025 Pay Revealed
OMEROS CORP ($OMER) CEO Gregory A. Demopulos, M.D., is estimated to have received $17,858,391 in compensation in 2025, a 30.75% increase from 2024, based on a new SEC filing. Insider trading activity for OMER shows 2 sales by DAVID J. BORGES totaling over $750,000 in the past six months, with no purchases. Additionally, institutional investors have shown mixed activity, with Morgan Stanley and Polar Asset Management decreasing positions significantly, while UBS Group AG, Vanguard Group Inc, and Susquehanna International Group, LLP increased their holdings.
OMEROS CORP ($OMER) CEO 2025 Pay Revealed
OMEROS CORP's CEO, Gregory A. Demopulos, M.D., is estimated to have received $17,858,391 in compensation in 2025, marking a 30.75% increase from 2024, based on a recent DEF14A SEC filing. The article also details recent insider trading activity, showing two sales by a VP, as well as institutional investor movements, analyst ratings, and price targets for $OMER stock.
Executive pay, incentives and votes detailed in Omeros (NASDAQ: OMER) 2026 proxy
Omeros Corporation (NASDAQ: OMER) has released its 2026 proxy statement, detailing executive compensation, corporate governance, and proposals for its upcoming annual meeting. Shareholders will vote on the election of three Class II directors, an advisory "say-on-pay" resolution for executive compensation, approval of an amended incentive plan, and the ratification of Ernst & Young LLP as auditor. The board recommends voting "FOR" all proposals, emphasizing the company's strong performance in 2025, including FDA approval of YARTEMLEA and a significant strategic transaction with Novo Nordisk.
Omeros (NASDAQ:OMER) Trading 6.3% Higher - Should You Buy?
Omeros (NASDAQ:OMER) saw its shares jump 6.3% during midday trading on Monday, reaching $14.3790 on light volume. Despite mixed analyst views, the consensus is a "Moderate Buy" with a target price of $40.33, following a Q1 EPS beat of $3.14 against estimates of ($0.55). Hedge funds and institutional investors have recently adjusted their holdings, with 48.79% of the company's stock owned by such entities.
Omeros (NASDAQ:OMER) Lowered to Hold Rating by Wall Street Zen
Wall Street Zen downgraded Omeros (NASDAQ:OMER) from a Buy to a Hold rating. Despite this, the biopharmaceutical company holds a "Moderate Buy" consensus rating from other analysts, with an average price target significantly above its current share price. Omeros recently reported strong quarterly earnings, beating analyst estimates, and institutional investors have been adjusting their positions in the stock.
how Fair Value analysis identified Omeros’ 74% biotech breakout By Investing.com
InvestingPro's Fair Value analysis accurately predicted a 74% breakout for Omeros Corporation (NASDAQ:OMER) by identifying the biotech stock as significantly undervalued in December 2024. The analysis, which incorporates multiple valuation methodologies, looked beyond current negative financials to assess the company's pipeline and market opportunity. Key developments like FDA approval of YARTEMLEA and a partnership with Novo Nordisk validated the bullish outlook, demonstrating the power of sophisticated valuation tools.
Omeros Corporation to acquire $80.5 million of its convertible senior notes due 2026
Omeros Corporation announced its intention to acquire $80.5 million aggregate principal amount of its 5.25% Convertible Senior Notes due 2026 through privately negotiated transactions. This move aims to reduce the company's debt and potentially benefit stockholders by improving its financial structure. The company plans to use a combination of cash on hand and a borrowing under its credit facility to fund these acquisitions.
Ingalls & Snyder (NASDAQ: OMER) holds 3.47M shares, 4.8% stake
Ingalls & Snyder, LLC has reported a beneficial ownership of 3,466,268 shares of Omeros Corp (OMER) common stock, representing a 4.8% stake in the company. This disclosure, an amendment to a previous Schedule 13G filing, indicates shared dispositive power over these shares and includes those from the assumed conversion of $550,000 in convertible bonds. As the position is below the 5% threshold, it is considered a routine disclosure of passive holdings.
Omeros Corporation to acquire $80.5 million of its convertible senior notes due 2026
Omeros Corporation will acquire $80.5 million of its convertible senior notes due 2026, which represents approximately 94% of the outstanding notes. The acquisition will be funded using cash proceeds from its Royalty Purchase Agreement. This move is expected to significantly reduce interest expenses and potential share dilution for the company.
Omeros Is Maintained at Buy by D. Boral Capital
Omeros (OMER) has received a reiterated "Buy" rating from D. Boral Capital. This indicates that the analyst firm maintains a positive outlook on the company's stock.
D. Boral Capital Reiterates "Buy" Rating for Omeros (NASDAQ:OMER)
D. Boral Capital has reaffirmed its "Buy" rating for Omeros (NASDAQ:OMER), setting a price target of $36, which suggests a 173% potential upside. Analyst sentiment for Omeros is generally positive, with a "Moderate Buy" consensus and an average price target of $40.33. The biopharmaceutical company recently reported an unexpected quarterly EPS of $3.14, significantly exceeding estimates, despite projections for a negative fiscal-year EPS.
Omeros (NASDAQ:OMER) Rating Increased to Buy at Wall Street Zen
Wall Street Zen upgraded Omeros (NASDAQ:OMER) from a "hold" to a "buy" rating, contributing to a "Moderate Buy" consensus among analysts with a $40.33 price target. The biopharmaceutical company recently reported a surprising quarterly EPS of $3.14, significantly beating analyst forecasts, although full-year EPS is still expected to be negative. Institutional investors, including Vanguard and UBS, have substantially increased their stakes in the company, which recently opened at $13.44.
OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment
Omeros (OMER) shares are poised for their best week in nearly four months after the U.S. Centers for Medicare and Medicaid Services (CMS) assigned a permanent J-code for its recently-approved treatment, Yartemlea. This J-code, effective July 1, simplifies billing and accelerates reimbursement for hospitals and clinics using the drug, which is the first and only FDA-approved medicine for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The company is also seeking European approval for Yartemlea by mid-2026, and retail traders have reacted bullishly to the news.
Omeros receives permanent J-code for TA-TMA treatment Yartemlea By Investing.com
Omeros Corporation has secured a permanent J-code (J1289) for its TA-TMA treatment, Yartemlea, which will become effective on July 1, 2026. This code will simplify billing and reimbursement for patients covered by U.S. government programs and commercial payers. The company also reported a significant earnings beat in Q4 2025, with analysts projecting profitability for fiscal year 2026 and maintaining a strong buy consensus.
Omeros says CMS assigns permanent reimbursement J-code for YARTEMLEA
Omeros Corporation announced that the U.S. Centers for Medicare & Medicaid Services has assigned a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for its product, YARTEMLEA. This J-code will streamline billing and reimbursement for YARTEMLEA for patients covered by U.S. government programs and commercial payers, becoming effective on July 1, 2026.
Omeros receives permanent J-code for TA-TMA treatment Yartemlea By Investing.com
Omeros Corporation has secured a permanent Healthcare Common Procedure Coding System J-code (J1289) for its TA-TMA treatment, Yartemlea, effective July 1, 2026. This code will simplify billing and reimbursement for the drug, which is FDA-approved for hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and children. Analysts project Omeros to turn profitable this year with strong buy ratings, and the company recently reported a significant Q4 2025 earnings beat.
New CMS billing code aims to speed patient access to YARTEMLEA
Omeros Corporation announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding System (HCPCS) J-code (J1289) for YARTEMLEA, effective July 1, 2026. This J-code will streamline billing and reimbursement for the drug, which is the first and only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The move is expected to reduce administrative burdens, support faster patient access, and provide more predictable reimbursement for healthcare providers.
Omeros Corporation (NASDAQ:OMER) Given Average Recommendation of "Moderate Buy" by Brokerages
Omeros Corporation (NASDAQ:OMER) has received a "Moderate Buy" consensus rating from six brokerages, with an average 12-month price target of $40.33, significantly higher than its current share price of $11.49. The company recently reported a surprisingly strong quarterly EPS of $3.14, beating estimates, despite analysts forecasting a negative full-year EPS. Insider David J. Borges sold 30,000 shares, while institutional investors like Vanguard and UBS materially increased their holdings.
OMER News | OMEROS CORP (NASDAQ:OMER)
This article provides news and financial updates for OMEROS CORP (NASDAQ: OMER). It highlights the company's current stock price, recent performance, and a report from 12 days prior detailing its Q4 2025 earnings, which were boosted by a major asset sale, and the launch of its first commercial product.
Does Omeros (OMER) Have the Potential to Rally 266.67% as Wall Street Analysts Expect?
Omeros (OMER) has garnered a consensus price target from Wall Street analysts suggesting a potential upside of 266.7%. While analyst price targets can be misleading, growing optimism regarding the company's earnings prospects and a Zacks Rank #1 (Strong Buy) rating indicate a potential upside for the stock. Investors should consider these factors in conjunction, not solely relying on price targets.
Omeros expects YARTEMLEA to be financially self-sustaining in 2026 and targets positive cash flow in 2027
Omeros Corporation anticipates its drug YARTEMLEA will achieve financial self-sustainability by 2026. The company also projects reaching overall positive cash flow by 2027. These targets indicate a positive outlook for Omeros's financial performance in the coming years.
Omeros Achieves Profitability as Strategic Moves Slash Debt
Omeros Corporation has become profitable, reporting an $86.5 million net profit in Q4 2025, largely due to a $240 million asset sale to Novo Nordisk. The company also significantly reduced its debt by 47% to $88 million and successfully launched its new drug YARTEMLEA. Future revenues are anticipated from additional milestones with Novo Nordisk and an upcoming EMA regulatory decision for YARTEMLEA.
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
Omeros Corporation announced its fourth quarter and year-end 2025 financial results, reporting a net income of $86.5 million for Q4 2025, largely due to a $237.6 million gain from the zaltenibart transaction with Novo Nordisk. The company also highlighted the FDA approval of YARTEMLEA® for TA-TMA and its ongoing commercial launch, alongside progress in its oncology and anti-infective programs. Omeros aims for positive cash flow by 2027, propelled by these strategic successes and pipeline advancements.
Omeros Sees Unusually Large Options Volume (NASDAQ:OMER)
Omeros (NASDAQ:OMER) experienced unusually high options volume, with investors acquiring 7,487 call options, a 54% increase from typical volume. This activity follows a strong Q4 earnings report where the company posted a GAAP net income of $86.5M and an EPS of $3.14, significantly beating expectations and causing the stock to rise by 15.3%. Despite mixed analyst ratings, the company has a consensus price target of $40.33, and institutional investors hold a substantial portion of its stock.
Transcript : Omeros Corporation, Q4 2025 Earnings Call, Mar 31, 2026
This article is a transcript of Omeros Corporation's Q4 2025 Earnings Call, held on March 31, 2026. The earnings call was published on April 1, 2026, at 3:35 am EDT. The full content is reserved for subscribers.
